Reading Time: 5 minutes While we work hard for a cure, it is essential we support those living with MND now. Professor Chris McDermott, Professor of Translational Neurology at the University of Sheffield, trial co-lead Maintaining quality of life and supporting psychological well-being are critical for individuals living with MND. However, there has been very little research on how…
Reading Time: 5 minutes Despite extensive research, the causes of MND remain largely unknown. Recent investigations have begun to shed light on the gut microbiome and whether it may have a role in the development and progression of MND, offering potential new avenues for understanding and possibly treating the disease. The gut microbiome refers to the community of microorganisms,…
Reading Time: 4 minutes This is blog number 5 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green text correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). The phenotype is the…
Reading Time: 3 minutes The Science Show on ABC Radio National in Australia, features an interview with Professor Justin Yerbury on Saturday 17th August. The article containing the interview titled ‘Resistant nerves could lead to treatment for neurodegenerative disease‘ is a fascinating insight into Prof Yerbury’s work on the delicate balance of proteins in solution within our nerves and…
Reading Time: 4 minutes In April this year MND clinician-researchers Professors Martin Turner and Kevin Talbot at the University of Oxford organised an information day about the rare, inherited form of MND called ‘Families for the Treatment of Hereditary MND’ (FATHoM). The day was filmed and podcasts of the talks have recently become available. This article gives an overview…
Reading Time: 5 minutes It’s been over a month since the announcement by the FDA of their decision to licence edaravone / Radicava for people with MND in the USA. The speed of the FDA’s decision took the drug company MT Pharma and the MND research community by suprise. It is encouraging that edaravone has been licenced to treat…
Reading Time: 4 minutes Each year, the MND Association dedicates the month of June to raising MND awareness. This year, we focus on the eyes – in most people with MND the only part of their body they can still move and the only way left for them to communicate. Alongside the Association-wide campaign, the Research Development team selected…
Reading Time: 2 minutes On Friday 5 May in America, the FDA, the organisation that approves drugs, announced that they’d granted a licence for the drug known as a Edaravone (to be marketed as Radicava ) for the treatment of MND. It’s unexpected news and we’re currently working out what this means for people with MND in the UK.…
Reading Time: 3 minutes A new research paper has been published today in the Science Translational Medicine journal, describing a new gene implicated in developing MND. What is this gene and why is it important for our fight against MND? Although they are not the sole cause of MND, genes play a big role in someone’s probability of developing the…
Reading Time: 3 minutes A recently published paper exploring the connection between occupational risk factors and MND has sparked lots of interest, especially by the media. The study in question, led by Dr Roel Vermeulen from Utrecht University, The Netherlands, reviewed and studied five occupational exposures that had previously been suggested to be associated with developing MND (specifically, amyotrophic…
